TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #15060 · Aug 15

#python#alibabacloud#android#android_emulator#aws#azure#cloud#docker#docker_android#emulator#gcp#genymotion#jenkins#kubernetes#mobile_app#mobile_web#novnc#saltstack#selenium#selenium_grid#terraform You can use Docker-Android to run Android emulators inside Docker containers, which helps you develop and test Android apps easily without needing physical devices. It offers many device profiles like Samsung Galaxy and Nexus models, supports viewing the emulator via VNC, sharing logs through a web interface, and controlling the emulator remotely with adb. It works on Ubuntu and can integrate with cloud services like Genymotion. This setup speeds up development, testing, and automation, making your workflow more consistent and efficient while saving resources. You can also persist data and run unit or UI tests with popular frameworks like Appium and Espresso. This helps you build and test Android apps faster and more reliably. https://github.com/budtmo/docker-android

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选
Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment